Kereos' targeted therapeutics and molecular imaging agents will enable clinicians to both diagnose disease in situ via definitive molecular markers and to deliver therapeutics exclusively to diseased tissue using those same biomarkers. In combination, they represent the most direct route to saving lives by exploiting the rapid advance of molecular medicine.

Using imaging agents driven by our knowledge of molecular biology, physicians will be able to peer non-invasively into a patient and detect disease with much the same precision as previously possible with biopsy and clinical pathology, and to do so on a whole body basis. Targeted therapeutics based on these same discoveries will allow the physician to treat disease specifically, effectively and with fewer side effects. Ultimately, molecular imaging and targeted therapy will be used in combination to diagnose, screen patients for appropriate therapy, deliver a quantifiable dose of effective therapy and monitor response. Kereos is one of the first companies to recognize these opportunities and is developing products that deliver on these promises… today.